HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More “Toxic Tub” Fallout: Senator Gillibrand Decries “Total Lack Of Oversight”

This article was originally published in The Rose Sheet

Executive Summary

Sen. Kirsten Gillibrand, D-N.Y., is the latest Democrat to speak out about what she perceives as "a complete and total lack of oversight" in the personal-care sector, based on findings from the Campaign for Safe Cosmetics "Toxic Tub" report

You may also be interested in...



“Safe Baby Products Act”

Sen. Kirsten Gillibrand, D-N.Y., introduces the "Safe Baby Products Act," which directs FDA to investigate cosmetics and personal care marketed to and used by children, according to April 29 release. Bill directs FDA "to test a wide range of children's personal-care products, publicly report the findings and establish good manufacturing practices to reduce or eliminate hazardous contaminants from products." The legislation responds to the Campaign for Safe Cosmetics' "Toxic Tub" report, which analyzed and identified children's products containing suspected carcinogens 1,4-dioxane and formaldehyde. At the time of the report's release, Gillibrand said she would explore legislation putting onus on FDA to more closely scrutinize baby products (1"The Rose Sheet" March 23, 2009, p. 3). Sens. Dianne Feinstein, D-Calif., and Charles Schumer, D-N.Y., are co-sponsors. Lisa Archer of the Campaign for Safe Cosmetics states: "This bill is a good step forward. ... Next we need to overhaul cosmetics laws so the FDA can fully assess and assure the safety of all personal-care products.

Safe Baby Products Act

Sen. Kirsten Gillibrand, D-N.Y., introduces S. 295 to direct FDA to investigate cosmetics and personal care marketed to and used by children, according to April 29 release. The bill also would require FDA "to test a wide range of children's personal-care products, publicly report the findings and establish good manufacturing practices to reduce or eliminate hazardous contaminants from products." The legislation responds to the Campaign for Safe Cosmetics' "Toxic Tub" report, which analyzed and identified children's products containing suspected carcinogens 1,4-dioxane and formaldehyde. At the time of the report's release, Gillibrand said she would explore legislation to have FDA more closely scrutinize baby products (1"The Rose Sheet" March 23, 2009, p. 3). Sens. Dianne Feinstein, D-Calif., and Charles Schumer, D-N.Y., are co-sponsors

“Safe Baby Products Act”

Sen. Kirsten Gillibrand, D-N.Y., introduces the "Safe Baby Products Act," which directs FDA to investigate cosmetics and personal care marketed to and used by children, according to April 29 release. Bill directs FDA "to test a wide range of children's personal-care products, publicly report the findings and establish good manufacturing practices to reduce or eliminate hazardous contaminants from products." The legislation responds to the Campaign for Safe Cosmetics' "Toxic Tub" report, which analyzed and identified children's products containing suspected carcinogens 1,4-dioxane and formaldehyde. At the time of the report's release, Gillibrand said she would explore legislation putting onus on FDA to more closely scrutinize baby products (1"The Rose Sheet" March 23, 2009, p. 3). Sens. Dianne Feinstein, D-Calif., and Charles Schumer, D-N.Y., are co-sponsors. Lisa Archer of the Campaign for Safe Cosmetics states: "This bill is a good step forward. ... Next we need to overhaul cosmetics laws so the FDA can fully assess and assure the safety of all personal-care products.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016041

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel